文献速递妇科产科

组织学确诊子宫内膜异位症与卵巢癌发病风险的人群队列研究

Incidence of endometrioid and clear-cell ovarian cancer in histological proven endometriosis: the ENOCA population-based cohort study.
PubMed 文献 · Am J Obstet Gynecol · 2020-01-23

基于荷兰全国病理登记库,纳入131,450例子宫内膜异位症女性与132,654例皮肤良性痣女性对照,随访至2017年。年龄调整后卵巢癌总体发病率比为7.18,子宫内膜样癌和透明细胞癌的年龄调整发病率比分别为29.06和21.34;排除诊断后不足1人年随访者后总体风险无显著升高,但透明细胞癌和子宫内膜样癌风险仍显著升高。

要点

  • 组织学确诊子宫内膜异位症女性总体卵巢癌发病风险显著升高(年龄调整IRR 7.18)。
  • 子宫内膜样癌和透明细胞癌风险升高最显著(年龄调整IRR分别为29.06和21.34)。
  • 排除诊断后不足1人年随访者,总体卵巢癌风险无显著升高,但两种亚型风险仍显著升高。

核心结论

  • 组织学确诊子宫内膜异位症女性透明细胞癌和子宫内膜样癌发病率显著升高。
  • 所有卵巢癌亚型发病率均升高,但部分病例为绝经后同步诊断。

研究设计与样本

  • 基于荷兰全国病理登记库(PALGA)的人群队列研究。
  • 纳入1990–2015年组织学诊断子宫内膜异位症女性131,450例。
  • 对照为按年龄和纳入年份匹配的132,654例良性皮肤痣女性。
  • 检索1990年1月至2017年7月卵巢、输卵管和腹膜癌组织学诊断。

主要发现

  • 卵巢癌总体粗发病率比4.79(95%CI 4.33–5.31),年龄调整发病率比7.18(95%CI 6.17–8.36)。
  • 子宫内膜样癌年龄调整发病率比29.06(95%CI 20.66–40.87),透明细胞癌21.34(95%CI 14.01–32.51)。
  • 子宫内膜异位症队列卵巢癌诊断中位年龄56岁(IQR 49–63),痣队列60岁(IQR 53–67),P<.05。
  • 排除诊断后不足1人年随访者,总体卵巢癌粗发病率比1.04(95%CI 0.91–1.19),年龄调整发病率比1.08(95%CI 0.87–1.35)。
  • 排除后透明细胞癌年龄调整发病率比2.29(95%CI 1.24–4.20),子宫内膜样癌2.56(95%CI 1.47–4.47)。

临床怎么用

  • 对组织学确诊子宫内膜异位症女性应关注透明细胞癌和子宫内膜样癌的长期风险。
  • 绝经后平均年龄以上仍应警惕卵巢癌风险,即使临床子宫内膜异位症症状已消失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several studies have suggested that endometriosis is associated with an increased risk of ovarian cancer, especially for the clear-cell and endometrioid subtypes. However, previous studies lack sufficient power or diagnostic certainty. OBJECTIVE: The objective of the study was to assess the association between histologically proven endometriosis and ovarian cancer in a large population-based cohort study. STUDY DESIGN: We identified 131,450 women with a histological diagnosis of endometriosis between 1990 and 2015 from the Dutch nationwide registry of histopathology and cytopathology (PALGA). For the control cohort 132,654 women with a benign dermal nevus were matched on age and inclusion year with the endometriosis cases. Histological diagnoses of ovarian, fallopian tubes, and peritoneal cancers between January 1990 and July 2017 were retrieved. Incidence rate ratios were estimated for ovarian cancer and its subtypes for the whole follow-up period as well as for women with more than 1 person-year at risk. RESULTS: We found a crude incidence rate ratio of 4.79 (95% confidence interval, 4.33-5.31) and an age-adjusted incidence rate ratio of 7.18 (95% confidence interval, 6.17-8.36) for ovarian cancer overall. Endometrioid and clear-cell ovarian cancer had the highest age-adjusted incidence rate ratio of 29.06 (95% confidence interval, 20.66-40.87) and 21.34 (95% confidence interval, 14.01-32.51), respectively. Median age at ovarian cancer diagnosis was 56 years (interquartile range, 49-63) for the endometriosis cohort and 60 years (interquartile range, 53-67) for the nevus cohort, (P < .05). After excluding women with less than 1 person-year at risk following an endometriosis diagnosis, we found a crude incidence rate ratio of 1.04 (95% confidence interval, 0.91-1.19) and an age-adjusted incidence rate ratio of 1.08 (95% confidence interval, 0.87-1.35) for ovarian cancer overall. However, statistically significant age-adjusted incidence rate ratios of 2.29 (95% confidence interval, 1.24-4.20) for clear-cell ovarian cancer and 2.56 (95% confidence interval, 1.47-4.47) for endometrioid ovarian cancer were found. CONCLUSION: A significantly higher incidence of clear-cell and endometrioid ovarian cancer was found in women with histologically proven endometriosis. Additionally, we found an increased incidence of all ovarian cancer subtypes in histologically proven endometriosis; however, in many of these women, endometriosis and ovarian cancer were diagnosed synchronously after the average menopausal age, which may suggest that the risk of ovarian cancer in endometriosis patients remains, even when clinical endometriosis symptoms are no longer present.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Hermens M, van Altena AM, Nieboer TE, et al. Incidence of endometrioid and clear-cell ovarian cancer in histological proven endometriosis: the ENOCA population-based cohort study. Am J Obstet Gynecol. 2020. PMID: 31981507. doi:10.1016/j.ajog.2020.01.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。